Skip to main content

Table 1 Baseline characteristics of breast cancer with liver metastases at diagnosis in the SEER database

From: Risk and prognostic factors of breast cancer with liver metastases

Variable Patients, No. %
Total (n = 311,573) With Liver Metastases (n = 4067)
Age, y
 18–40 21,313 (6.8%) 494 (12.1%)
 41–60 137,299 (44.1%) 1882 (46.3%)
 61–80 129,497 (41.6%) 1414 (34.8%)
  > 80 23,464 (7.5%) 277 (6.8%)
Race
 White 207,400 (66.6%) 2565 (63.1%)
 Black 35,062 (11.3%) 737 (18.1%)
 Hispanic 37,499 (12.0%) 427 (10.5%)
 Asian or Pacific Islander 27,997 (9.0%) 305 (7.5%)
 American Indian/Alaska Native 1757 (0.6%) 23 (0.6%)
 Unknown 1858 (0.6%) 10 (0.2%)
Marital status
 Unmarried a 123,349 (39.6%) 2011 (49.4%)
 Married 171,728 (55.1%) 1827 (44.9%)
 Unknown 16,496 (5.3%) 229 (5.6%)
Insurance status
 Uninsured b 5417 (1.7%) 163 (4.0%)
 Insured 300,400 (96.4%) 3821 (94.0%)
 Unknown 5756 (1.8%) 83 (2.0%)
Histology
 Infiltrating duct carcinoma 234,958 (75.4%) 2971 (73.1%)
 Lobular carcinoma 27,050 (8.7%) 246 (6.0%)
 Infiltrating duct and lobular carcinoma 16,392 (5.3%) 133 (3.3%)
 Other types c 33,173 (10.6%) 717 (17.6%)
Pathological Grade
 I 66,365 (21.3%) 144 (3.5%)
 II 129,786 (41.6%) 1147 (28.2%)
 III/IV 98,850 (31.7%) 1939 (47.7%)
 Unknown 16,572 (5.3%) 837 (20.6%)
Surgery of primary site
 Yes 285,989 (91.8%) 952 (23.4%)
 No 22,831 (7.3%) 3052 (75.0%)
 Unknown 2753 (0.9%) 63 (1.5%)
Radiotherapy
 Yes 162,703 (52.2%) 1082 (26.6%)
 No/Unknown 148,870 (47.8) 2985 (73.4%)
Chemotherapy
 Yes 130,572 (42.0%) 2802 (68.9%)
 No/Unknown 181,001 (58.1%) 1265 (31.1%)
Extrahepatic metastatic sites to lung, brain and bone, No
 0 298,407 (95.8%) 1060 (26.1%)
 1 9408 (3.0%) 1696 (41.7%)
 2 2747 (0.9%) 891 (21.9%)
 All 3 343 (0.1%) 177 (4.4%)
 Unknown 668 (0.2%) 243 (6.0%)
Subtype
 HR+/HER2− 211,127 (67.8%) 1612 (39.6%)
 HR+/HER2+ 32,962 (10.6%) 884 (21.7%)
 HR−/HER2+ 14,089 (4.5%) 601 (14.8%)
 Triple-negative 33,352 (10.7%) 544 (13.4%)
 Unknown 20,043 (6.4%) 426 (10.5%)
  1. Notes: a including divorced, separated, single (never married), and widowed; b including insured, Insured/No specifics Any Medicaid; c including other histology of invasive breast cancer except Infiltrating duct carcinoma, Lobular carcinoma and Infiltrating duct and lobular carcinoma; + denotes positive; − denotes negative; * denotes a statistically significant P-value; HER2 Human epidermal growth factor receptor 2, HR Hormone receptor, OR Odds ratio, CI Confidence interval